ARA-290

ARA-290 (also referred to in research literature as cibinetide) is a synthetic, non-erythropoietic peptide engineered to mimic a structurally restricted region of the erythropoietin (EPO) molecule. It is an 11-amino-acid sequence modeled on the helix B surface of EPO, the portion thought in research to interact with the innate repair receptor rather than the classical erythropoietin receptor associated with red-blood-cell production. Because this domain is isolated from the hematopoietic-stimulating part of the parent molecule, ARA-290 is studied as a tool for probing tissue-protective and repair-associated signaling separate from the erythropoietic activity of full-length EPO. Supplied as a lyophilized powder for laboratory and professional research applications, ARA-290 is provided strictly for research and professional use and is not approved by the FDA for therapeutic use. Within this catalog it falls under the Healing and Recovery category as a compound of interest in preclinical and exploratory studies. Any effects discussed in the literature are context-dependent, and individual results vary.

• Investigated in preclinical literature for its proposed role in modulating tissue-protective and repair-associated signaling pathways; individual results vary
• Studied in research models for its reported interaction with inflammatory and neuroimmune signaling mediators
• Explored in exploratory studies addressing peripheral nerve and small-fiber-associated research endpoints
• Examined in preclinical work focused on cellular stress responses and tissue-recovery-associated processes
• Referenced in research literature as a non-erythropoietic comparator for studying EPO-derived signaling separate from red-blood-cell production

Reference handling information for research and professional use only. ARA-290 is typically supplied as a lyophilized powder and is commonly reconstituted with bacteriostatic or sterile water added slowly against the inside wall of the vial, then gently swirled rather than shaken until fully dissolved. Prior to reconstitution, the sealed lyophilized vial is generally stored frozen or refrigerated and protected from light, heat, and moisture. After reconstitution, the solution is generally kept refrigerated, protected from light, and handled using standard aseptic laboratory technique; reconstituted peptide is generally regarded as unsuitable for long-term storage per general peptide-handling references. Avoid repeated freeze-thaw cycles and exposure to direct light or elevated temperatures, which may affect peptide stability. All reconstitution parameters, concentrations, and clinical protocols are determined solely by the licensed ordering provider at their own professional discretion; this is reference information only and not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, ARA-290 is described as a selective agonist of the so-called innate repair receptor, a proposed heteromeric complex composed of the beta-common receptor subunit paired with the erythropoietin receptor. Because the peptide is derived from a non-hematopoietic surface of the EPO molecule, it is studied as a means of engaging this repair-associated pathway while reportedly bypassing the classical erythropoietin receptor associated with red-blood-cell production. Investigators have explored, in preclinical and exploratory models, whether activation of this pathway is associated with downstream modulation of inflammatory mediators, cellular stress responses, and tissue-repair signaling. These mechanistic descriptions reflect proposed and studied models rather than established clinical effects, and individual results vary.